Navigation Links
Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
Date:7/11/2011

ulatory cell activation, known to have immune suppressive effects, adds to our prior findings and suggests Ii-Key hybrids could have potential in the field of cancer immunotherapy," he added.  Jos van der Woert, who has accepted the position of Chief Executive Officer of Antigen Express, commented:  "This study further supports the differentiating profile of AE37 with other cancer immunotherapies and provides additional momentum to AE37's clinical development."

Prior clinical studies of an Ii-Key hybrid peptide being developed by Antigen Express, AE37, including a Phase I trial in patients with prostate cancer and a separate trial in patients with breast cancer, have been reported as the subject of four publications in leading peer-reviewed journals.  In brief, those studies showed that AE37 is safe, well-tolerated, and produced immunological responses that were above-and-beyond what had been hoped for.  When compared with two other HER-2 vaccines that have been evaluated in the clinic, AE37 produced the greatest HER-2-related delayed-type hypersensitivity (DTH) reactions in immunized patients.  Of all immunological responses examined in patients undergoing active immunotherapy for cancer, it has been argued that a strong DTH response most reliably predicts efficacy.  In addition, it was found that AE37 was the only peptide able to generate an immunological response when administered without an adjuvant (co-stimulatory agent).  Finally, (as indicated above) AE37 also was the only peptide shown to decrease the level of T regulatory cells.

A controlled, randomized, and single-blinded Phase II clinical study of AE37 in HER-2 expressing breast cancer patients is currently underway to establish clinical efficacy.  The study endpoint is a reduction in cancer relapse after two years compared to the current standard of care treatment.  There are currently over 200 patients enrolled in the study with either node pos
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
2. Generex Provides Clarification of Facts
3. Generex Announces Results of Annual Stockholders Meeting
4. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
5. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
6. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
7. Generex Announces $3.0 Million Capital Investment
8. Generex Provides Additional Details for October 21st Live Video Webcast
9. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
10. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
11. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... uBiome and OpenBiome Partner ... mechanics of fecal microbiota transplantation in C. difficile patients. , SAN FRANCISCO, uBiome ... undergoing fecal microbiota transplantation (FMT) as a treatment for Clostridium difficile infections (C. ...
(Date:6/30/2015)... CO (PRWEB) , ... June 30, 2015 , ... ... today announced that it has hired Gem Swartz to head up its account management ... senior account director. Both Gem and Amanda bring senior account management and delivery expertise ...
(Date:6/30/2015)... 2015  The Dr. Samadi Prostate Cancer Center in ... full suite of new genetic testing methods for men with ... prostate cancer. Dr. Samadi,s Prostate Cancer ... assessing the risk and optimizing the diagnosis of prostate cancer, ... to now offer these revolutionary genetic tests to men with ...
(Date:6/29/2015)... ... June 30, 2015 , ... This cutting edge standard making ... Featuring 12 distinct peaks, the WAV-8 is the world’s first cuvette-shaped, solid-state filter ... deep into the NIR range. Previous spectrophotometer calibration standards, such as those made from ...
Breaking Biology Technology:uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3Matrix Marketing Group Expands Client Services Team 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 3
... and VANCOUVER, Nov. 5 /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals (NASDAQ: ... results will be released on Monday, November 10, 2008,and ... live webcast at 4:30,p.m. EDT that afternoon. Management will ... on the business and product pipeline., To access ...
... 192% from third quarter 2007, - New business awards of $212 ... $1 billion at Sept. 30, 2008, up 16% ... from Dec. 31, 2007, ... research organization, today reported,record net income of $11.0 million or $0.73 per diluted ...
... CALGARY, Nov. 4 /PRNewswire-FirstCall/ - Oncolytics Biotech ... announced its,financial results for the three and ... Pivotal Trial Decision, Oncolytics made a ... pivotal (Phase,II/III) randomized trial using the combination ...
Cached Biology Technology:OncoGenex Pharmaceuticals to Release Third Quarter Financial Results 2Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 2Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 3Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 4Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 5Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 6Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 7Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 8Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 2Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 3Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 4Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 5Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 6Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 7Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 8Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 9
(Date:6/17/2015)... HILDEN , Deutschland und GERMANTOWN, Maryland ... Investigator ®   Produktlinie mit ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... neue STR-Testkits der Produktlinie Investigator ... DNA-Spuren in den Markt eingeführt. Die neuen Kits zur ...
(Date:6/17/2015)... 17, 2015  Crossmatch™, a leading provider of ... U.are.U ® 4500 fingerprint readers have been ... Inc., a San Jose, CA ... security, improve accountability and reduce fraud at the ... identity confirmation for employee sign in and transaction ...
(Date:6/16/2015)... 2015 Fingerprint Cards has received an ... the company,s portfolio from one of its module partners in ... take place during the third quarter 2015. The sensors will ... . Jörgen Lantto, CEO of FPC, comments: " ... growing interest from smartphone OEMs in integrating touch fingerprint sensors ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2
... An experimental vaccine applied the surface of the skin ... Scientists from the Research Institute at Nationwide Children,s ... the 109th General Meeting of the American Society for ... to show that transcutaneous immunization is an effective way ...
... the scourge of Britain,s roads! But now scientists and ... motorists caused by the repair, maintenance and upgrading of ... new technology will allow workers to virtually ,see, underground ... The University of Nottingham on June 11th brings together ...
... University of Minnesota, addressing long-standing conflicts in ecology ... the future of community ecology. The team ... evolutionary relationships among different species phylogenetics ... The work, published in the May issue of ...
Cached Biology News:Preventing ear infections in the future: Delivering vaccine through the skin 2Reducing the roadworks 2Reducing the roadworks 3U of Minnesota research reveals critical role of evolutionary processes in species coexistence 2
Adhesive seal-tab, for HybriWell™ hybridization sealing system *set of 400*...
...
... Platypus Contact Printing Kit contains choice of ... series of 100 / 200 micron squares ... 200 um x 10 mm lines, 3 ... 40 or 60 nm and pitch of ...
...
Biology Products: